Home    Back

 192. Cockayne syndrome
 [ 4 clinical trials,    7 drugs(DrugBank: 3 drugs),    1 target gene / 43 target pathways

Searched query = "Cockayne syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1ChiCTR19000267192019-11-0121 October 2019Clinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndromeClinical study for combined application of vitamin C and quercetin in the treatment of Cockayne's syndromeCockayne's syndrometest group:Vitamin C and Quercetin;The First Medical Center of PLA General HospitalNot Recruiting613Bothtest group:20;Phase 0China
2NCT02960997May 20167 October 2019Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) StudyA Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne SyndromeDrug: Sirolimus, 2%;Drug: VehicleStanford UniversityNot recruiting4 YearsN/AAll8Phase 2United States
3NCT03016715May 201616 December 2017Using Topical Sirolimus 2% for Patients With Epidermolysis Bullous Simplex (EBS) StudyA Prospective, Double-Blind, Cross-Over, Pilot Study to Assess Safety and Efficacy of Topical Sirolimus 2% in the Treatment of Plantar Blistering in Patients With Epidermolysis Bullous Simplex (EBS)Epidermolysis Bullosa Simplex;Epidermolysis Bullosa Simplex Kobner;Weber-Cockayne SyndromeDrug: Sirolimus 2%;Drug: VehiclePremier Specialists, AustraliaRecruiting5 YearsN/AAll8Phase 2Australia
4NCT01142154June 201019 February 2015Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne SyndromeA Phase I/II Crossover Study To Evaluate and Compare the Pharmacokinetics of a Single IV Dose of D-Mannitol (Osmitrol®10%) to Single and Multiple, Escalating Doses of Liquid, Oral Prodarsan™ in Patients With Cockayne SyndromeCockayne SyndromeDrug: ProdarsanDNage B.V.Not recruiting2 Years10 YearsBoth5Phase 1/Phase 2United States